PHAXIAM Therapeutics (XPAR:PHXM) EV-to-EBIT : 1.03 (As of May. 15, 2024)

View and export this data going back to 2013. Start your Free Trial

What is PHAXIAM Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PHAXIAM Therapeutics's Enterprise Value is €-3.43 Mil. PHAXIAM Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was €-3.32 Mil. Therefore, PHAXIAM Therapeutics's EV-to-EBIT for today is 1.03.

The historical rank and industry rank for PHAXIAM Therapeutics's EV-to-EBIT or its related term are showing as below:

XPAR:PHXM' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.18 Med: 0 Max: 30.58
Current: 1.03

During the past 11 years, the highest EV-to-EBIT of PHAXIAM Therapeutics was 30.58. The lowest was -13.18. And the median was 0.00.

XPAR:PHXM's EV-to-EBIT is ranked better than
65.44% of 434 companies
in the Biotechnology industry
Industry Median: 9.44 vs XPAR:PHXM: 1.03

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. PHAXIAM Therapeutics's Enterprise Value for the quarter that ended in Sep. 2023 was €29.74 Mil. PHAXIAM Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was €-3.32 Mil. PHAXIAM Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -11.16%.

PHAXIAM Therapeutics EV-to-EBIT Historical Data

The historical data trend for PHAXIAM Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PHAXIAM Therapeutics EV-to-EBIT Chart

PHAXIAM Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

Get a 7-Day Free Trial

0.53

-0.98

-1.77

-1.11

-22.62

PHAXIAM Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial															0.70	-1.25	-22.62	-8.36	-8.96

Competitive Comparison of PHAXIAM Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, PHAXIAM Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PHAXIAM Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PHAXIAM Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PHAXIAM Therapeutics's EV-to-EBIT falls into.

PHAXIAM Therapeutics EV-to-EBIT Calculation

PHAXIAM Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-3.426	/	-3.32
	=	1.03

PHAXIAM Therapeutics's current Enterprise Value is €-3.43 Mil.
PHAXIAM Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.32 Mil.

PHAXIAM Therapeutics (XPAR:PHXM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

PHAXIAM Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	-3.32	/	29.7364397
	=	-11.16 %

PHAXIAM Therapeutics's Enterprise Value for the quarter that ended in Sep. 2023 was €29.74 Mil.
PHAXIAM Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.32 Mil.

PHAXIAM Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

PHAXIAM Therapeutics (XPAR:PHXM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (XPAR:PHXM) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

PHXM:USA 2E41:Germany

Address

60 Avenue Rockefeller, Lyon, FRA, 69008

Website

https://www.erytech.com

Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.